Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19
Although corticosteroid therapy is the standard of care for all patients hospitalized with severe coronavirus disease 2019 (COVID-19), the studies demonstrating the mortality–benefit ratio of corticosteroids were limited to fully evaluate their adverse effects. To determine the severity of corticost...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2542454822000492 |
| _version_ | 1797997407161548800 |
|---|---|
| author | Kirk B. Fetters, M.D Stephen P. Judge, MD Eric S. Daar, MD Timothy J. Hatlen, MD |
| author_facet | Kirk B. Fetters, M.D Stephen P. Judge, MD Eric S. Daar, MD Timothy J. Hatlen, MD |
| author_sort | Kirk B. Fetters, M.D |
| collection | DOAJ |
| description | Although corticosteroid therapy is the standard of care for all patients hospitalized with severe coronavirus disease 2019 (COVID-19), the studies demonstrating the mortality–benefit ratio of corticosteroids were limited to fully evaluate their adverse effects. To determine the severity of corticosteroid-induced hyperglycemia in patients with and without diabetes mellitus, we retrospectively collected data from the medical records of patients hospitalized with COVID-19 before and after corticosteroids were the standard of care. Corticosteroid-induced hyperglycemia was more severe in patients hospitalized with COVID-19 with diabetes than those without diabetes. Additionally, patients with diabetes required higher doses of correctional insulin per day when on corticosteroid therapy, suggesting that intensive point-of-care glucose monitoring could be limited in patients without diabetes mellitus and support cautionary use of corticosteroids in patients with COVID-19 discharged with supplemental oxygen. |
| first_indexed | 2024-04-11T10:32:38Z |
| format | Article |
| id | doaj.art-72b2f531ccb64709bb9fcee97ee8729f |
| institution | Directory Open Access Journal |
| issn | 2542-4548 |
| language | English |
| last_indexed | 2024-04-11T10:32:38Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
| spelling | doaj.art-72b2f531ccb64709bb9fcee97ee8729f2022-12-22T04:29:23ZengElsevierMayo Clinic Proceedings: Innovations, Quality & Outcomes2542-45482022-10-0165484487Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19Kirk B. Fetters, M.D0Stephen P. Judge, MD1Eric S. Daar, MD2Timothy J. Hatlen, MD3Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA; Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CAKaiser Permanente Los Angeles Medical Center, Los Angeles, CADepartment of Medicine, Harbor-UCLA Medical Center, Torrance, CA; Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CADepartment of Medicine, Harbor-UCLA Medical Center, Torrance, CA; Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA; Correspondence: Address to Timothy J. Hatlen, MD, Harbor-UCLA Medical Center, 1000 W Carson St, Box 466, Torrance, CA 90509.Although corticosteroid therapy is the standard of care for all patients hospitalized with severe coronavirus disease 2019 (COVID-19), the studies demonstrating the mortality–benefit ratio of corticosteroids were limited to fully evaluate their adverse effects. To determine the severity of corticosteroid-induced hyperglycemia in patients with and without diabetes mellitus, we retrospectively collected data from the medical records of patients hospitalized with COVID-19 before and after corticosteroids were the standard of care. Corticosteroid-induced hyperglycemia was more severe in patients hospitalized with COVID-19 with diabetes than those without diabetes. Additionally, patients with diabetes required higher doses of correctional insulin per day when on corticosteroid therapy, suggesting that intensive point-of-care glucose monitoring could be limited in patients without diabetes mellitus and support cautionary use of corticosteroids in patients with COVID-19 discharged with supplemental oxygen.http://www.sciencedirect.com/science/article/pii/S2542454822000492 |
| spellingShingle | Kirk B. Fetters, M.D Stephen P. Judge, MD Eric S. Daar, MD Timothy J. Hatlen, MD Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19 Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
| title | Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19 |
| title_full | Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19 |
| title_fullStr | Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19 |
| title_full_unstemmed | Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19 |
| title_short | Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19 |
| title_sort | burden of hyperglycemia in patients receiving corticosteroids for severe covid 19 |
| url | http://www.sciencedirect.com/science/article/pii/S2542454822000492 |
| work_keys_str_mv | AT kirkbfettersmd burdenofhyperglycemiainpatientsreceivingcorticosteroidsforseverecovid19 AT stephenpjudgemd burdenofhyperglycemiainpatientsreceivingcorticosteroidsforseverecovid19 AT ericsdaarmd burdenofhyperglycemiainpatientsreceivingcorticosteroidsforseverecovid19 AT timothyjhatlenmd burdenofhyperglycemiainpatientsreceivingcorticosteroidsforseverecovid19 |